Generic Name and Formulations:
Velaglucerase alfa 400 Units/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Shire US, Inc.
Indications for VPRIV:
Long-term enzyme replacement therapy (ERT) in patients with Type 1 Gaucher disease.
Adults and Children:
<4yrs: not established. Give by IV infusion over 60 minutes. Individualize. ≥4yrs: 60 Units/kg every other week; adjust dose based on therapeutic goals. Begin treatment with Vpriv at the same dose when switching from imiglucerase.
Monitor for hypersensitivity reactions; immediately discontinue and treat appropriately if occur. Temporarily discontinue and resume with increased infusion time, slowing infusion rate, or administer antihistamines, antipyretics, and/or corticosteroids if infusion-related reactions occur. Elderly. Pregnancy (Cat.B). Nursing mothers.
Lysosomal glucocerebroside-specific enzyme.
Infusion-related reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, upper respiratory tract infection, activated PTT prolonged, fatigue/asthenia, pyrexia.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL